Followers | 4 |
Posts | 108 |
Boards Moderated | 0 |
Alias Born | 11/07/2014 |
Thursday, September 27, 2018 9:26:47 AM
Recent ALDX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease • Business Wire • 05/08/2024 11:00:00 AM
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 • Business Wire • 04/18/2024 11:00:00 AM
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease • Business Wire • 03/28/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 09:54:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:48:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/07/2024 09:40:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:06:42 PM
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 10:25:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:00:30 PM
- Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases • Business Wire • 01/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:05:14 PM
- Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis • Business Wire • 12/19/2023 12:00:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM